Busulfan

證據等級: L5

預測適應症: 10 個

BUSULFAN: From Chronic Myelogenous Leukemia to Myelodysplastic Syndrome

One-Sentence Summary

Busulfan is a bifunctional alkylating agent historically used as conditioning therapy before allogeneic hematopoietic stem cell transplantation (HSCT) in leukemia and other hematologic malignancies. The TxGNN model predicts it may be effective for Myelodysplastic Syndrome (MDS), with 50 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Chronic myelogenous leukemia (CML); HSCT conditioning for hematologic malignancies (global approvals; no SFDA registration)
Predicted New Indication	Myelodysplastic Syndrome
TxGNN Prediction Score	99.62%
Evidence Level	L1
Saudi Arabia Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the structured database. Based on known information, busulfan is a bifunctional alkylating agent that exerts its effect through DNA cross-linking, causing irreversible inhibition of rapidly proliferating cells — particularly hematopoietic progenitor cells. This myeloablative property forms the mechanistic basis for its decades-long role as conditioning therapy before allogeneic HSCT. The drug's efficacy in eliminating abnormal hematopoietic clones in leukemia is well established, and this mechanism is directly applicable to MDS.

In MDS, the core pathology involves clonal abnormalities in hematopoietic stem cells resulting in ineffective hematopoiesis and progressive risk of leukemic transformation. Busulfan's myeloablative action eliminates these abnormal hematopoietic clones and creates the necessary engraftment space for donor cells in allogeneic HSCT. Intravenous busulfan combined with fludarabine (Bu/Flu regimen) has become one of the standard conditioning approaches for MDS patients undergoing HSCT, achieving effective clearance of abnormal clones with manageable toxicity — and this is explicitly reflected in the mechanistic link described for this indication.

Both the original application (leukemia) and the predicted new indication (MDS) are clonal hematopoietic disorders where myeloablation is the therapeutic rationale. This mechanistic overlap is reinforced by four Phase 3 randomized controlled trials in the literature directly studying busulfan-based conditioning in MDS, along with more than 50 clinical trials across multiple HSCT platforms, together justifying the L1 evidence classification.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06477549	Phase 2	Recruiting	220	Direct RCT comparing benadamustine vs ruxolitinib added to fludarabine/busulfan conditioning for haploidentical HSCT in MDS/myelofibrosis; the most current randomized evidence with busulfan as the core conditioning backbone
NCT02250937	Phase 2	Active, not recruiting	116	Venetoclax + timed sequential busulfan + cladribine + fludarabine before allogeneic HSCT for AML and MDS; directly and prospectively tests busulfan as the core drug in MDS conditioning
NCT00863148	Phase 2	Completed	30	Clofarabine + IV busulfan + thymoglobulin (CBT) reduced-intensity conditioning prior to HSCT for high-risk AML, MDS, or ALL; demonstrated anti-tumor efficacy with manageable toxicity
NCT00301834	Phase 2	Completed	35	Fludarabine + busulfan + alemtuzumab reduced-toxicity conditioning for children with stem cell defects, marrow failure, or MDS undergoing allogeneic HSCT
NCT00186342	N/A	Completed	120	Allogeneic sibling and unrelated donor HCT with busulfan + etoposide + cyclophosphamide for MDS and myeloproliferative disorders; assessed tolerability and efficacy in patients aged 51–60
NCT02221310	Phase 2	Completed	25	Gemtuzumab ozogamicin + busulfan + cyclophosphamide followed by allogeneic HSCT for high-risk AML and MDS; evaluated targeted immunochemotherapy combined with busulfan myeloablation
NCT01643668	Phase 2	Completed	34	Reduced-intensity conditioning with busulfan/clofarabine prior to allogeneic HSCT; tested novel busulfan-based combination in MDS and AML setting
NCT02626715	Phase 2	Completed	21	Myeloablative vs reduced-intensity conditioning for children and young adults with AML/MDS undergoing HSCT; compared two busulfan-based conditioning regimens for toxicity and efficacy
NCT00521430	N/A	Completed	30	Non-T-cell depleted HLA-haploidentical familial donor HSCT after reduced-intensity busulfan conditioning; provided important safety data for busulfan RIC in MDS and bone marrow failure
NCT05027945	Phase 2	Recruiting	54	Allogeneic HSCT for VEXAS syndrome, which shares MDS-like clonal bone marrow abnormalities; busulfan-containing conditioning regimen used to achieve myeloablation

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36702138	2023	RCT	The Lancet Haematology	Phase 3 open-label multicenter RCT: G-CSF + decitabine added to busulfan-cyclophosphamide conditioning significantly reduced relapse vs busulfan-cyclophosphamide alone in MDS-RAEB and secondary AML undergoing allogeneic HSCT
31606445	2020	Phase 3 RCT	The Lancet Haematology	MC-FludT.14/L trial: treosulfan-fludarabine was non-inferior to reduced-intensity busulfan-fludarabine in older or comorbid AML/MDS patients; validated busulfan-flu as the reference standard comparator
35617104	2022	RCT (Phase 3, final analysis)	American Journal of Hematology	Final analysis of 476-patient Phase 3 RCT showing treosulfan non-inferior to reduced-intensity busulfan for event-free survival in older AML/MDS patients undergoing allogeneic HCT
28380315	2017	Phase III RCT	Journal of Clinical Oncology	BMT CTN Phase III randomized trial comparing myeloablative (including busulfan-based) vs reduced-intensity conditioning in AML and MDS patients undergoing allogeneic HCT; found comparable OS with different toxicity-relapse tradeoffs
40079242	2025	Review	American Journal of Hematology	Contemporary review of allogeneic HSCT for MDS and myelofibrosis; confirms busulfan-based conditioning regimens as central to curative treatment strategy for eligible higher-risk MDS patients
33425740	2020	Systematic Review & Meta-analysis	Frontiers in Oncology	Systematic review and meta-analysis comparing treosulfan- vs busulfan-based conditioning for MDS/AML before allogeneic HCT; pooled analysis of long-term outcomes and toxicity
37579918	2023	Prospective Cohort	Transplantation and Cellular Therapy	Myeloablative busulfan + fludarabine with in vivo T-cell depletion shown safe and effective for AML and MDS patients undergoing allogeneic HSCT regardless of age or HCT-CI score
38648898	2024	Retrospective Cohort	Transplantation and Cellular Therapy	Single-center propensity score-matched comparison of treosulfan- vs busulfan-based conditioning in 138 MDS patients at Princess Margaret Hospital (2015–2022)
34489555	2021	Retrospective Cohort	Bone Marrow Transplantation	Nationwide Japanese registry analysis (2006–2018): fludarabine/busulfan (Flu/Bu4) vs busulfan/cyclophosphamide (Bu4/Cy) myeloablative conditioning specifically for MDS patients
38176654	2024	Retrospective Cohort	Transplantation and Cellular Therapy	Italian pediatric multicenter study assessing long-term toxicities (growth, gonadal, thyroid, cardiac) after HSCT with treosulfan- or busulfan-based conditioning in children with acute leukemia or MDS

Saudi Arabia Market Information

Busulfan currently has no registered product authorizations with the Saudi Food and Drug Authority (SFDA). The drug is not marketed in Saudi Arabia. Any clinical use would require import authorization or regulatory submission through SFDA.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Bifunctional alkylating agent (busulfan class; cell-cycle non-specific)
Myelosuppression Risk	High — Myelosuppression is the intended pharmacological mechanism; complete bone marrow ablation is the therapeutic goal in HSCT conditioning. Universal and severe pancytopenia (neutropenia, thrombocytopenia, anemia) occurs following high-dose administration and persists until donor engraftment
Emetogenicity Classification	Moderate to high (IV high-dose regimen); low to moderate (oral dosing)
Monitoring Items	CBC with differential (daily during conditioning and engraftment period), liver function tests (hepatic sinusoidal obstruction syndrome / VOD risk is significant with high-dose busulfan), therapeutic drug monitoring (TDM — AUC-guided dosing recommended for IV busulfan), renal function, neurological status (seizure risk at myeloablative doses — prophylactic anticonvulsants, typically phenytoin or levetiracetam, are required)
Handling Protection	Must follow cytotoxic drug handling regulations for both oral tablet and IV formulations; standard PPE and closed-system drug transfer devices required during IV preparation

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple Phase 3 randomized controlled trials directly studying busulfan-based conditioning in MDS patients confirm its clinical utility, with the evidence meeting L1 criteria. The mechanistic rationale is sound — busulfan's myeloablative effect is precisely what is needed to eliminate abnormal hematopoietic clones before allogeneic HSCT. However, the complete absence of SFDA registration is a critical regulatory gap, and full safety data from a structured source was not available in this evidence pack.

To proceed, the following is needed:

Regulatory pathway: Obtain SFDA import authorization or initiate product registration for busulfan (IV and/or oral) in Saudi Arabia before clinical deployment
Safety documentation: Review full prescribing information from FDA/EMA label, particularly for hepatic veno-occlusive disease (VOD) monitoring, seizure prophylaxis protocol, and contraindications
Pharmacokinetic monitoring protocol: Establish therapeutic drug monitoring (TDM) capability for IV busulfan AUC-guided dosing; this is standard of care to minimize toxicity variability
Drug interaction screening: Conduct formal drug-drug interaction assessment (DDI data not available in this evidence pack), particularly for co-medications affecting busulfan metabolism (CYP3A4 interactions)
Institutional HSCT program readiness: Confirm that the treating institution has an established allogeneic HSCT program with expertise in busulfan-based conditioning, supportive care infrastructure (including engraftment monitoring), and GVHD management capability
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.